Tissue Regenix Group PLC Publication of Financial Results (0406I)
March 16 2018 - 11:40AM
UK Regulatory
TIDMTRX
RNS Number : 0406I
Tissue Regenix Group PLC
16 March 2018
Tissue Regenix Group plc
Publication of Financial Results
Leeds, 16 March 2018 - Tissue Regenix Group (AIM:TRX) ("Tissue
Regenix" or "The Group") the regenerative medical devices company
announces that the audit process of its annual financial statements
is still ongoing and the audited results for year ended 31 December
2017 will now be announced on Monday 26 March 2018. The Board is
satisfied that there are no negative issues and trading remains in
line with Board expectations.
For more Information:
Tissue Regenix Group plc Tel:
Caitlin Pearson Head of Communications 0330 430
3073 / 07920272
441
---------------------------------------- -----------------
Jefferies International Ltd Tel:
Simon Hardy / Christopher Binks 020 7029
8000
---------------------------------------- -----------------
FTI Consulting Tel:
Brett Pollard / Mo Noonan/ Rob Winder 0203 727
1000
======================================== =================
About Tissue Regenix
Tissue Regenix is a leading medical devices company in the field
of regenerative medicine. Tissue Regenix was formed in 2006 when it
was spun-out from the University of Leeds, UK. The company's
patented decellularisation ('dCELL(R) ') technology removes DNA and
other cellular material from animal and human soft tissue leaving
an acellular tissue scaffold which is not rejected by the patient's
body and can then be used to repair diseased or worn out body
parts. Current applications address many critical clinical needs
such as sports medicine, heart valve replacement and wound
care.
In November 2012 Tissue Regenix Group plc set up a subsidiary
company in the United States - 'Tissue Regenix Wound Care Inc.',
January 2016 saw the establishment of joint venture GBM-V, a multi-
tissue bank based in Rostock, Germany.
In August 2017 Tissue Regenix acquired CellRight Technologies(R)
, a biotech company that specializes in regenerative medicine and
is dedicated to the development of innovative osteoinductive and
wound care scaffolds that enhance healing opportunities of defects
created by trauma and disease. CellRight's human osteobiologics may
be used in spine, trauma, general orthopedic, foot & ankle,
dental, and sports medicine surgical procedures.
This information is provided by RNS
The company news service from the London Stock Exchange
END
NORFKADNPBKDBND
(END) Dow Jones Newswires
March 16, 2018 11:40 ET (15:40 GMT)
Tissue Regenix (LSE:TRX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Tissue Regenix (LSE:TRX)
Historical Stock Chart
From Jul 2023 to Jul 2024